1
|
Önal G, Levent A. Electrochemical evaluation and determination of vindesine used in cancer chemotherapy at disposable pencil graphite electrode by voltammetric method. MONATSHEFTE FÜR CHEMIE - CHEMICAL MONTHLY 2023; 154:205-213. [DOI: https:/doi.org/10.1007/s00706-023-03038-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/08/2022] [Accepted: 01/08/2023] [Indexed: 07/01/2024]
|
2
|
Önal G, Levent A. Electrochemical evaluation and determination of vindesine used in cancer chemotherapy at disposable pencil graphite electrode by voltammetric method. MONATSHEFTE FUR CHEMIE 2023. [DOI: 10.1007/s00706-023-03038-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
|
3
|
Tolcher AW. Antibody drug conjugates: The dos and don'ts in clinical development. Pharmacol Ther 2022; 240:108235. [PMID: 35738430 DOI: 10.1016/j.pharmthera.2022.108235] [Citation(s) in RCA: 13] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2022] [Revised: 06/14/2022] [Accepted: 06/16/2022] [Indexed: 12/15/2022]
Abstract
Antibody Drug Conjugates (ADCs) entered clinical trials in the mid 1990s to selectively deliver cytotoxic chemotherapy to cancer cells with the goal to increase the antitumor activity and decrease normal tissue toxicity. Over nearly 30 years of development the ADC platform has become established with now 11 approved agents and many more in the pipeline. This review is designed to highlight some of the problems and solutions encountered in clinical development as well as provide practical instruction to both clinical investigators on the efficient protocol design for ADCs and the lessons learned.
Collapse
Affiliation(s)
- Anthony W Tolcher
- Director for Clinical Research, NEXT Oncology, 2829 Babcock Road Suite 300, San Antonio, TX 78229, United States of America.
| |
Collapse
|
4
|
Barreca M, Stathis A, Barraja P, Bertoni F. An overview on anti-tubulin agents for the treatment of lymphoma patients. Pharmacol Ther 2020; 211:107552. [PMID: 32305312 DOI: 10.1016/j.pharmthera.2020.107552] [Citation(s) in RCA: 35] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2020] [Accepted: 04/14/2020] [Indexed: 01/19/2023]
Abstract
Anti-tubulin agents constitute a large class of compounds with broad activity both in solid tumors and hematologic malignancies, due to the interference with microtubule dynamics. Since microtubules play crucial roles in the regulation of the mitotic spindles, the interference with their function usually leads to a block in cell division with arrest at the metaphase/anaphase junction of mitosis, followed to apoptosis. This explains the reason why tubulin-binding agents (TBAs) proved to be extremely active in patients with cancer. Several anti-tubulin agents are indicated in the treatment of patients with lymphomas both alone and in combination chemotherapy regimens. The article reviews the literature on classic and more recent anti-tubulin agents, providing an insight into their mechanisms of action and their use in the treatment of lymphoma.
Collapse
Affiliation(s)
- Marilia Barreca
- Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Palermo, Italy; Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland
| | - Anastasios Stathis
- Oncology Institute of Southern Switzerland, Bellinzona, Switzerland,; Faculty of Biomedical Sciences, USI, Lugano, Switzerland
| | - Paola Barraja
- Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Palermo, Italy
| | - Francesco Bertoni
- Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland,; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland,.
| |
Collapse
|
5
|
Wang JH, Li MJ, Tang DX, Xu S, Mao JQ, Cai JB, He M, Shu Q, Lai C. Neoadjuvant transcatheter arterial chemoembolization and systemic chemotherapy for treatment of clear cell sarcoma of the kidney in children. J Pediatr Surg 2019; 54:550-556. [PMID: 30318310 DOI: 10.1016/j.jpedsurg.2018.09.012] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/02/2017] [Revised: 08/27/2018] [Accepted: 09/24/2018] [Indexed: 12/18/2022]
Abstract
BACKGROUND Clear cell sarcoma of the kidney (CCSK) is a rare and aggressive malignant renal tumor. We describe our experience with neoadjuvant transcatheter arterial chemoembolization (TACE) and systematic chemotherapy for the treatment of advanced CCSK in children. METHODS Between January 2010 and December 2016, seven patients (3 boys and 4 girls; median 2.2 years) with advanced CCSK received preoperative TACE of renal artery and systemic chemotherapy. The chemoembolic emulsion for TACE consisted of cisplatin, pirarubicin, vindesine, and iodized oil. Preoperative systemic chemotherapy with vindesine, ifosfamide, and etoposide was administered three weeks after TACE. Nephrectomy was performed three weeks after systemic chemotherapy. After surgery, patients received radiotherapy and postoperative chemotherapy. RESULTS No cardiotoxicity, renal insufficiency, or hepatic dysfunction was found in any patients. Grade II-III marrow suppression developed in four patients. One patient with tumor progress during neoadjuvant therapy failed to successfully undergo surgery and died. Six patients underwent nephrectomy after neoadjuvant therapy. Median follow-up period was 49.5 months (range, 11-83 months). Five patients have recurrence-free survival. One patient is still in postoperative chemotherapy after nephrectomy, radiotherapy and thoracoscopic resection of lung metastases. CONCLUSIONS Neoadjuvant TACE and systemic chemotherapy appeared to be feasible in the treatment of advanced CCSK in this pilot study. THE TYPE OF STUDY A case series with no comparison group. LEVEL OF EVIDENCE Level IV.
Collapse
Affiliation(s)
- Jin-Hu Wang
- Division of Surgical Oncology, Department of Pediatric Surgery, The Children's Hospital, Zhejiang University School of Medicine, No. 3333 Binsheng Road, 310052 Hangzhou, China.
| | - Min-Ju Li
- Division of Surgical Oncology, Department of Pediatric Surgery, The Children's Hospital, Zhejiang University School of Medicine, No. 3333 Binsheng Road, 310052 Hangzhou, China.
| | - Da-Xing Tang
- Division of pediatric urology, Department of Pediatric Surgery, The Children's Hospital, Zhejiang University School of Medicine, No. 3333 Binsheng Road, 310052 Hangzhou, China.
| | - Shan Xu
- Division of pediatric urology, Department of Pediatric Surgery, The Children's Hospital, Zhejiang University School of Medicine, No. 3333 Binsheng Road, 310052 Hangzhou, China.
| | - Jun-Qing Mao
- Division of Surgical Oncology, Department of Pediatric Surgery, The Children's Hospital, Zhejiang University School of Medicine, No. 3333 Binsheng Road, 310052 Hangzhou, China.
| | - Jia-Bin Cai
- Division of Surgical Oncology, Department of Pediatric Surgery, The Children's Hospital, Zhejiang University School of Medicine, No. 3333 Binsheng Road, 310052 Hangzhou, China.
| | - Min He
- Division of Surgical Oncology, Department of Pediatric Surgery, The Children's Hospital, Zhejiang University School of Medicine, No. 3333 Binsheng Road, 310052 Hangzhou, China.
| | - Qiang Shu
- Division of Surgical Oncology, Department of Pediatric Surgery, The Children's Hospital, Zhejiang University School of Medicine, No. 3333 Binsheng Road, 310052 Hangzhou, China.
| | - Can Lai
- Department of Radiology, The Children's Hospital, Zhejiang University School of Medicine, No. 3333 Binsheng Road, 310052 Hangzhou, China.
| |
Collapse
|
6
|
Sheng Y, Liu K, Wu Q, Oi N, Chen H, Reddy K, Jiang Y, Yao K, Li H, Li W, Zhang Y, Saleem M, Ma WY, Bode AM, Dong Z, Dong Z. PPMP, a novel tubulin-depolymerizing agent against esophageal cancer in patient-derived tumor xenografts. Oncotarget 2016; 7:30977-89. [PMID: 27129160 PMCID: PMC5058732 DOI: 10.18632/oncotarget.9050] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2015] [Accepted: 04/10/2016] [Indexed: 11/29/2022] Open
Abstract
Esophageal cancer is one of the least studied and deadliest cancers worldwide with a poor prognosis due to limited options for treatment. Chemotherapy agents such as the microtubule-targeting compounds are the mainstay of palliation for advanced esophageal cancer treatment. However, the toxicity and side effects of tubulin-binding agents (TBAs) have promoted the development of novel, more potent but less toxic TBAs. Herein, we identified 2-[4-(3,4-dimethoxyphenyl)-3-methyl-1H-pyrazol-5-yl]-5-[(2-methylprop-2-en-1-yl)oxy] phenol (PPMP) as a novel TBA for esophageal cancer treatment. PPMP markedly inhibited tubulin polymerization, and decreased viability and anchorage-independent growth of esophageal cancer cell lines, effects that were accompanied by G2/M arrest and apoptosis. Importantly, we produced patient-derived esophageal cancer xenografts to evaluate the therapeutic effect of PPMP in a setting that best mimics the clinical context in patients with esophageal cancer. Overall, we identified PPMP as a novel microtubule-destabilizing compound and as a new therapeutic agent against esophageal carcinoma.
Collapse
Affiliation(s)
- Yuqiao Sheng
- Basic Medical College, Zhengzhou University, Zhengzhou, Henan, China
- The Hormel Institute, University of Minnesota, Austin, Minnesota, USA
- The First Affiliated Hospital, Zhengzhou University, Zhengzhou, China
| | - Kangdong Liu
- Basic Medical College, Zhengzhou University, Zhengzhou, Henan, China
- The Hormel Institute, University of Minnesota, Austin, Minnesota, USA
- China-US (Henan) Hormel Cancer Institute, ZhengZhou, Henan, China
| | - Qiong Wu
- Basic Medical College, Zhengzhou University, Zhengzhou, Henan, China
- China-US (Henan) Hormel Cancer Institute, ZhengZhou, Henan, China
| | - Naomi Oi
- The Hormel Institute, University of Minnesota, Austin, Minnesota, USA
| | - Hanyong Chen
- The Hormel Institute, University of Minnesota, Austin, Minnesota, USA
| | - Kanamata Reddy
- The Hormel Institute, University of Minnesota, Austin, Minnesota, USA
| | - Yanan Jiang
- Basic Medical College, Zhengzhou University, Zhengzhou, Henan, China
| | - Ke Yao
- The Hormel Institute, University of Minnesota, Austin, Minnesota, USA
| | - Haitao Li
- The Hormel Institute, University of Minnesota, Austin, Minnesota, USA
| | - Wei Li
- The Hormel Institute, University of Minnesota, Austin, Minnesota, USA
| | - Yi Zhang
- Basic Medical College, Zhengzhou University, Zhengzhou, Henan, China
- The Hormel Institute, University of Minnesota, Austin, Minnesota, USA
- The First Affiliated Hospital, Zhengzhou University, Zhengzhou, China
- China-US (Henan) Hormel Cancer Institute, ZhengZhou, Henan, China
| | - Mohammad Saleem
- The Hormel Institute, University of Minnesota, Austin, Minnesota, USA
| | - Wei-Ya Ma
- The Hormel Institute, University of Minnesota, Austin, Minnesota, USA
| | - Ann M. Bode
- The Hormel Institute, University of Minnesota, Austin, Minnesota, USA
| | - Ziming Dong
- Basic Medical College, Zhengzhou University, Zhengzhou, Henan, China
| | - Zigang Dong
- Basic Medical College, Zhengzhou University, Zhengzhou, Henan, China
- The Hormel Institute, University of Minnesota, Austin, Minnesota, USA
- China-US (Henan) Hormel Cancer Institute, ZhengZhou, Henan, China
| |
Collapse
|
7
|
Zhu RH, Li HD, Cai HL, Jiang ZP, Xu P, Dai LB, Peng WX. Validated HILIC-MS/MS assay for determination of vindesine in human plasma: Application to a population pharmacokinetic study. J Pharm Biomed Anal 2014; 96:31-6. [PMID: 24721203 DOI: 10.1016/j.jpba.2014.03.017] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2013] [Revised: 03/11/2014] [Accepted: 03/13/2014] [Indexed: 10/25/2022]
Abstract
The first HILIC-tandem mass spectrometry (MS/MS) method for determination of vindesine (VDS) in human plasma using vinorelbine as an internal standard (IS) has been developed and validated. Plasma samples clean-up consisted of solid phase extraction with a strata™-X column. The compounds were separated on a HILIC column with an isocratic mobile phase consisting of acetonitrile and 15mM ammonium acetate buffer containing 0.15% formic acid (80:20, v/v). The detection was performed on a triple quadrupole tandem mass spectrometer via electrospray positive ionization (ESI(+)). The ion transitions recorded in multiple reaction monitoring mode were m/z 754.6→123.8 for VDS and 779.4→323.3 for IS, respectively. Linear calibration curves were obtained in the concentration range of 0.3-28ng/ml and the lower limit of quantification for VDS was 0.3ng/ml. The coefficient of variation of the assay precision was less than 13%, and the accuracy exceeded 96%. The developed assay method was successfully applied for the evaluation of population pharmacokinetics of VDS after intravenous infusion of Xi Ai Ke Vial(®) (3mg of Vindesine Sulfate for Injection) to Chinese Han subjects with hematological malignant disorders.
Collapse
Affiliation(s)
- Rong-Hua Zhu
- Clinical Pharmacy and Pharmacology Research Institute, the Second Xiang-Ya Hospital, Central-South University, Changsha, Hunan Province 410011, People's Republic of China; School of Pharmacy, Central-South University, Changsha 410005, People's Republic of China.
| | - Huan-De Li
- Clinical Pharmacy and Pharmacology Research Institute, the Second Xiang-Ya Hospital, Central-South University, Changsha, Hunan Province 410011, People's Republic of China
| | - Hua-Lin Cai
- Clinical Pharmacy and Pharmacology Research Institute, the Second Xiang-Ya Hospital, Central-South University, Changsha, Hunan Province 410011, People's Republic of China
| | - Zhi-Ping Jiang
- Laboratory of Clinical Pharmacology, Department of Hematology, Xiang-Ya Hospital, Central-South University, Changsha 410008, People's Republic of China
| | - Ping Xu
- Clinical Pharmacy and Pharmacology Research Institute, the Second Xiang-Ya Hospital, Central-South University, Changsha, Hunan Province 410011, People's Republic of China
| | - Li-Bo Dai
- Clinical Pharmacy and Pharmacology Research Institute, the Second Xiang-Ya Hospital, Central-South University, Changsha, Hunan Province 410011, People's Republic of China; School of Pharmacy, Central-South University, Changsha 410005, People's Republic of China
| | - Wen-Xing Peng
- Clinical Pharmacy and Pharmacology Research Institute, the Second Xiang-Ya Hospital, Central-South University, Changsha, Hunan Province 410011, People's Republic of China
| |
Collapse
|
8
|
Kai K, Satoh H, Kajimura T, Kato M, Uchida K, Yamaguchi R, Tateyama S, Furuhama K. Olfactory epithelial lesions induced by various cancer chemotherapeutic agents in mice. Toxicol Pathol 2005; 32:701-9. [PMID: 15580704 DOI: 10.1080/01926230490524283] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
In order to examine and compare the potential toxicity in the olfactory epithelium, the antitumor drug vincristine sulfate (VCR), vinblastine sulfate(VBL), vindesine sulfate (VDS), paclitaxel (PTX), mitomycin C (MMC), 5-fluorouracil, (5-FU) or cisplatin (CDDP) was intravenously injected once(designated as day 1) at an estimated 10% lethal dose (LD(10)) to male BALB/c mice. The animals were necropsied on days 2, 5 and 15, and nasal tissues were examined by light-microscopy, counting of epithelial cells positive for terminal deoxyribonucleotidyl transferase-mediated dUTP-digoxigenin nick-end labeling (TUNEL), immunohistochemical staining with keratin antibody, and electron microscopy. Further, to delineate the drug disposition in the target organ, whole-body radioluminography was performed 1 hour and 24 hours after treatment with the LD(10) of PTX or 5-FU. Of the antitumor drugs employed, only the antimicrotubule agents, VCR, VBL, VDS, and PTX, induced single cell death in the olfactory epithelium, especially sensory cells on day 2, atrophy of the olfactory epithelium on day 5, and myelin fragmentation in the trigeminal nerve on day 15. PTX induced the strongest changes among the 4 antimicrotubule agents. The cell death was confirmed to be apoptosis by TUNEL assay and electron microscopy, whereas the change in horizontal basal cells of the olfactory epithelium was shown not to be apoptosis by keratin staining. In quantitative radioluminography,radioactivity of PTX in the nasal tissues both 1 hour and 24 hours after administration was about 4- or 5-fold higher than those of 5-FU. These results suggest that tubulin-targeting antitumour drugs could induce apoptosis in the olfactory epithelial cells of mice and that high drug distribution may effect the onset of the olfactory lesions.
Collapse
Affiliation(s)
- Kiyonori Kai
- Drug Safety Research Laboratory, Daiichi Pharmaceutical Co., Ltd., 1-16-13 Kitakasai, Edogawa-ku, Tokyo 134-8630, Japan.
| | | | | | | | | | | | | | | |
Collapse
|
9
|
Sørensen JB, Bergman B, Nielsen AL, Krarup M, Dombernowsky P, Hansen HH. Phase II study of gemcitabine and vindesine in patients with previously untreated non-resectable non-small-cell lung cancer. Br J Cancer 1999; 79:875-81. [PMID: 10070884 PMCID: PMC2362682 DOI: 10.1038/sj.bjc.6690140] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/03/2022] Open
Abstract
Because both vindesine and gemcitabine are active drugs in advanced non-small-cell lung cancer (NSCLC), with different modes of action and only partly overlapping toxicity, a phase II study was performed. Gemcitabine 1000 mg m(-2) was given on days 1, 8 and 15 every 4 weeks, while vindesine 3 mg m(-2) was administered weekly for 7 weeks, then every 2 weeks. A total of 42 patients with nonresectable NSCLC were included. The median age of patients was 56 years; 57% were men, 52% had adenocarcinoma, 31% squamous cell carcinoma and 17% had large-cell carcinoma. The performance status ranged from 0 to 2 with 83% in performance status 1. The majority (55%) had stage IV disease, while 40% had stage III B and 5% stage III A disease. WHO grade 3-4 leucopenia occurred in five patients (12%) and 9% had grade 4 neutropenia. Thrombocytopenia grade 3-4 was observed in six patients (15%). There were no septic death or bleeding episodes. One patient had a transient WHO grade 4 increase in bilirubin, and four patients had a decrease in glomerular filtration rate below the normal limit; one of these patients developed a non-reversible renal insufficiency. Ten patients (24%) complained of dyspnoea of uncertain mechanism, possibly involving bronchoconstriction. There were one complete and seven partial responses among 40 assessable patients (20%, 95% confidence limits 9-36%). Median response duration was 31 weeks (range 11-83 weeks) and median survival time 31 weeks (range 2-171 weeks). The current combination of gemcitabine and vindesine does not appear to be promising for further examination because of the toxicity and somewhat disappointing activity.
Collapse
Affiliation(s)
- J B Sørensen
- Department of Oncology, Finsen Center, National University Hospital, Copenhagen, Denmark
| | | | | | | | | | | |
Collapse
|
10
|
Abstract
Despite lack of cross-resistance with vincristine and a somewhat different toxicity spectrum, the semi-synthetic vinca alkaloid, vindesine, has not yet achieved its expected potential in the treatment of acute leukaemias. The ability of vindesine to induce remissions in vincristine-resistant and relapsed ALL is of particular interest for the development of potentially curative second-line regimens. Vindesine may also have a role in consolidation strategies for de novo ALL, although it will be difficult to demonstrate specific advantages for this agent as part of a multidrug treatment approach. In myeloid leukaemias, while vindesine appears to have a limited role in ANLL, it may be useful for the palliative treatment of CML blast crisis. In the future, new synergistic combinations, incorporating vindesine with for example, methotrexate or edatrexate, may be developed.
Collapse
Affiliation(s)
- N Gökbuget
- Klinikum der Johann Wolfgang Goethe-Universität Frankfurt am Main, Frankfurt, Germany
| | | |
Collapse
|
11
|
Sørensen JB, Hansen HH. Is there a role for vindesine in the treatment of non-small cell lung cancer? Invest New Drugs 1993; 11:103-33. [PMID: 8262725 DOI: 10.1007/bf00874146] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Vindesine is a semisynthetic derivative of vinblastine which has been evaluated in clinical studies since the late 1970's. The literature on vindesine in the treatment of non-small cell lung cancer has been reviewed and all aspects of vindesine treatment in this disease has been covered. It is concluded that vindesine as a single agent yields a response rate of 18% based on the treatment of 295 patients included in phase II trials (95% confidence limits 13%-22%). No difference was observed among the three major histologic types of non-small cell lung cancer. In phase III trials, the response rate and confidence limits are at a similar level. Combination chemotherapy including vindesine plus cisplatin ranks among the most active treatments in non-small cell lung cancer and is as active as etoposide plus cisplatin, both with respect to response rate and survival. It has not been documented that the addition of one or two other drugs to the combination of vindesine yields an increase in survival. When best supportive care was compared with a combination of vindesine plus cisplatin, the group with chemotherapy was attributed a survival advantage in all three studies published, and the difference was statistically significant in two of these three studies. Thus, vindesine has a well documented activity in non-small cell lung cancer and ranks among the most active single agents in this disease. Vindesine is also part of several active combination chemotherapies among which the combination of vindesine plus cisplatin is particularly interesting, because it has been repeatedly shown to prolong survival as compared to supportive care. Especially this latter point leads to the conclusion that there is a role for vindesine in the treatment of non-small cell lung cancer. However, the concept of chemotherapy in this disease remains investigational even though the advances seen in recent years clearly merit further studies.
Collapse
Affiliation(s)
- J B Sørensen
- Department of Oncology, Rigshospitalet, Copenhagen, Denmark
| | | |
Collapse
|
12
|
Abstract
PURPOSE to review the neurotoxicity associated with antineoplastic agents. METHODS four hundred articles, abstracts and book chapters were selected for review. One hundred and ninety (articles, book chapters and abstracts) were identified as representative of the important aspects of neurotoxicity to be presented in this review. RESULTS in general the dose, schedule and route of administration significantly determine the incidence and outcome of antineoplastic agents neurotoxicity. An updated and detailed review of neurotoxicity is provided with special attention to vinca alkaloids, cisplatin and biologic response modifiers. The neurotoxic side effects of some of the new approaches in cancer therapy and some of the investigational agents are discussed. Guidelines for the prevention and management of this toxicity are presented. In addition, suggestions are made in regard to the preclinical and clinical screening of new agents for neurotoxicity. CONCLUSION quality of life issues have become a focal point in many clinical trials. Neurotoxicity associated with antineoplastic therapy clearly has an impact on the short and long term quality of the life of cancer patients. A better understanding of this toxicity requires developing reliable and predictive models to screen new agents prior to their introduction into clinical trials; a more detailed and uniform grading system; and the prospective evaluation of neurotoxicity in clinical trials of new antineoplastic agents.
Collapse
Affiliation(s)
- M Hussain
- Department of Medicine, Wayne State University School of Medicine, Detroit, MI 48201
| | | | | |
Collapse
|
13
|
Rowinsky EK, Donehower RC. The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics. Pharmacol Ther 1991; 52:35-84. [PMID: 1687171 DOI: 10.1016/0163-7258(91)90086-2] [Citation(s) in RCA: 220] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Although there has been a rapid expansion of the number of classes of compounds with antineoplastic activity, few have played a more vital role in the curative and palliative treatment of cancers than the antimicrotubule agents. Although the vinca alkaloids have been the only subclass of antimicrotubule agents that have had broad experimental and clinical applications in oncologic therapeutics over the last several decades, the taxanes, led by the prototypic agent taxol, are emerging as another very active class of antimicrotubule agents. After briefly reviewing the mechanisms of antineoplastic action and resistance, this article comprehensively reviews the clinical pharmacology, therapeutic applications, and clinical toxicities of selected antimicrotubule agents.
Collapse
Affiliation(s)
- E K Rowinsky
- Division of Pharmacology and Experimental Therapeutics, Johns Hopkins Oncology Center, Baltimore, Maryland 21205
| | | |
Collapse
|
14
|
Cersosimo RJ, Bromer R, Licciardello JT, Hong WK. Pharmacology, clinical efficacy and adverse effects of vindesine sulfate, a new vinca alkaloid. Pharmacotherapy 1983; 3:259-74. [PMID: 6359081 DOI: 10.1002/j.1875-9114.1983.tb03269.x] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
Vindesine is a new vinca alkaloid antineoplastic agent derived from vinblastine. However, its antineoplastic spectrum more closely resembles that of vincristine. Clinical studies indicate activity against acute leukemia, lung cancer, carcinoma of the breast, squamous cell carcinoma of the esophagus and head and neck, Hodgkin's disease and non-Hodgkin's lymphomas. Pharmacokinetic studies indicate that vindesine exhibits a triphasic elimination pattern with a terminal half-life of 24.2 hours. Elimination is primarily through hepatic metabolism. The major side effects associated with vindesine therapy are myelosuppression and neurotoxicity. Other side effects include alopecia, nausea and vomiting and local tissue irritation associated with extravasation. Vindesine will be a positive addition to the antineoplastic armamentarium. The full extent of its activity remains to be established.
Collapse
|
15
|
Pazdur R, Rossof AH, Chandra G, Bonomi PD, Slayton RE, Wolter J. Vindesine: phase II evaluation in colon cancer and description of its platelet stimulating activity. Cancer Chemother Pharmacol 1982; 9:41-4. [PMID: 7139851 DOI: 10.1007/bf00296760] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
Fifteen previously treated patients with measurable metastatic colon carcinoma were entered into a phase II study of vindesine, 3 mg/m2/week IV. Fourteen patients were evaluable for response. No objective tumor response was observed; however, seven patients experienced stable disease lasting 9, 10, 13, 15, 16, 19, and 26 weeks. Neurologic toxicity was the most common nonhematologic side-effect noted, manifesting as abdominal pain, constipation, paralytic ileus, or paresthesias. Leukopenia was observed in 16% of the 104 weekly courses. Nine patients had a 50% increase of their platelet counts above their pretreatment platelet counts; six patients had a doubling of their pretreatment platelet counts. Mean platelet counts revealed a linear increase with successive treatments during the initial 8 weeks of therapy. Serial CEA determinations demonstrated a parallel relationship with clinical progression in six of seven patients.
Collapse
|